147 related articles for article (PubMed ID: 37913733)
1. I-CBP112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs.
Strachowska M; Gronkowska K; Sobczak M; Grodzicka M; Michlewska S; Kołacz K; Sarkar T; Korszun J; Ionov M; Robaszkiewicz A
Biomed Pharmacother; 2023 Dec; 168():115798. PubMed ID: 37913733
[TBL] [Abstract][Full Text] [Related]
2. CBP/p300 Bromodomain Inhibitor-I-CBP112 Declines Transcription of the Key ABC Transporters and Sensitizes Cancer Cells to Chemotherapy Drugs.
Strachowska M; Gronkowska K; Michlewska S; Robaszkiewicz A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572840
[TBL] [Abstract][Full Text] [Related]
3. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
[TBL] [Abstract][Full Text] [Related]
4. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.
Vesel M; Rapp J; Feller D; Kiss E; Jaromi L; Meggyes M; Miskei G; Duga B; Smuk G; Laszlo T; Karner I; Pongracz JE
Respir Res; 2017 Mar; 18(1):52. PubMed ID: 28340578
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
8. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.
Zhang H; Zhang YK; Wang YJ; Kathawala RJ; Patel A; Zhu H; Sodani K; Talele TT; Ambudkar SV; Chen ZS; Fu LW
Cancer Sci; 2014 Aug; 105(8):1071-8. PubMed ID: 24903205
[TBL] [Abstract][Full Text] [Related]
9. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
12. Activity of Lysosomal ABCC3, ABCC5 and ABCC10 is Responsible for Lysosomal Sequestration of Doxorubicin and Paclitaxel-Oregongreen488 in Paclitaxel-Resistant Cancer Cell Lines.
Gronkowska K; Michlewska S; Robaszkiewicz A
Cell Physiol Biochem; 2023 Sep; 57(5):360-378. PubMed ID: 37767694
[TBL] [Abstract][Full Text] [Related]
13. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
14. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
15. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
Heffeter P; Jakupec MA; Körner W; Chiba P; Pirker C; Dornetshuber R; Elbling L; Sutterlüty H; Micksche M; Keppler BK; Berger W
Biochem Pharmacol; 2007 Jun; 73(12):1873-86. PubMed ID: 17445775
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.
Duz MB; Karatas OF
Mol Biol Rep; 2021 Feb; 48(2):1393-1400. PubMed ID: 33506275
[TBL] [Abstract][Full Text] [Related]
18. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
19. KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer.
Jaromi L; Csongei V; Vesel M; Abdelwahab EMM; Soltani A; Torok Z; Smuk G; Sarosi V; Pongracz JE
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065402
[TBL] [Abstract][Full Text] [Related]
20. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]